Glymidine sodium

Glycodiazine
Clinical data
Routes of; administration	Oral
ATC code	A10BC01 (WHO) ;
Pharmacokinetic data
Bioavailability	High
Protein binding	90%
Elimination half-life	3.8 hours
Identifiers
	IUPAC name N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide;
CAS Number	339-44-6 ;
PubChem CID	9565;
DrugBank	DB01382 ;
ChemSpider	9190 ;
UNII	4C5I4BQZ8F;
ChEBI	CHEBI:31660;
ChEMBL	ChEMBL1697838 ;
CompTox Dashboard (EPA)	DTXSID1023108 ;
ECHA InfoCard	100.005.842
Chemical and physical data
Formula	C13H15N3O4S
Molar mass	309.34 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=S(=O)(Nc1ncc(OCCOC)cn1)c2ccccc2;
	InChI InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16) ; Key:QFWPJPIVLCBXFJ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Glymidine sodium (INN, also known as glycodiazine; trade name Gondafon) is a sulfonamide antidiabetic drug, structurally related to the sulfonylureas. It was first reported in 1964, and introduced to clinical use in Europe in the mid to late 1960s.^[1]

References

^ "Glymidine". British Medical Journal. 2 (5555): 817. June 1967. doi:10.1136/bmj.2.5555.817. PMC 1843097. PMID 6029147.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[BrMedJ-1] "Glymidine". British Medical Journal. 2 (5555): 817. June 1967. doi:10.1136/bmj.2.5555.817. PMC 1843097. PMID 6029147.

[1]